A new alternative to invasive, painful biopsies for determining heart transplant rejection is both available and ...
November 2006 - Physicians at UT Southwestern Medical Center are part of a multinational clinical trial evaluating the Optimizer System, a unique implantable device designed to treat a larger number of patients with heart failure. UT Southwestern is one of the top enrolling centers of the 50 sites in the U.S.
Results from the Danish SORT-OUT II study, the largest randomized trial to date comparing Taxus and Cypher drug-eluting ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Healthcare IT companies will again converge this winter to measure their ability to integrate with each other during the ...
A large California-based study has shown that patients with heart failure who start taking statins, compared with those who don't, will live longer and have a lower hospitalization risk regardless of cholesterol levels, presence or absence of coronary disease, and other CV drug therapies, “Heartwire” reported this week.
While general endotracheal anesthesia (GETA) is the most common type of anesthesia used in infrainguinal bypasses, a study published in the November issue of the Journal of Vascular Surgery reveals that it may not be the best strategy.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
The Certification Commission for Healthcare Information Technology is inviting organizations to submit their ambulatory ...
Agfa HealthCare has signed a multi-million dollar deal with Thomas Memorial Hospital in South Charleston, WV and will ...
The FDA has granted approval to Cook Inc. for its new 36mm Zenith FLEX AAA Endovascular Graft for the treatment of ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
British researchers have concluded that counseling and education aimed at preventing coronary heart disease have no impact on mortality and little effect in terms of clinical events, reports “heartwire.” Dr Shah Ebrahim (London School of Tropical Medicine, UK) and colleagues report their findings in the Oct. 18, 2006 Cochrane Database of Systematic Reviews.
TeraRecon Inc. and Commissure, Inc. have announced a partnership to integrate and deliver seamless workflow ...
A subset analysis of diabetic patients in the SPIRIT II Clinical trial of the XIENCE V Everolimus Eluting Stent System ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Cardium Therapeutics and its subsidiary InnerCool Therapies reported on preclinical data demonstrating a new and ...
Early clinical results from Abbott's ongoing ABSORB clinical trial, the world's first study to evaluate the safety and performance of a fully bioabsorbable drug-eluting stent platform for the treatment of coronary artery disease in humans, were presented during the 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.
GlaxoSmithKline and Flamel Technologies announced FDA approval of once-a-day Coreg CR (carvedilol phosphate) extended ...